NFKB1 and severe acute respiratory syndrome: Horowitz and Freeman (2020) hypothesized and recommended a randomized controlled trial by modulating NF-κB and subsequent cytokine formation to manage SARS-Cov-2 complications. An integrative pathway network analysis study illustrates that SARS-CoV-2 miRNAs target NF-KB, JAK/STAT3, TGF beta signaling transduction pathways, and cellular epigenetic regulation pathways (Aydemir et al., 2021).